# Intralesional Sclerosant for in Transit and Cutaneous Melanoma Metastases

> **NCT03754140** · PHASE2 · WITHDRAWN · sponsor: **Melanoma Institute Australia**

## Conditions studied

- Melanoma
- In-Transit Metastasis of Cutaneous Melanoma

## Interventions

- **DRUG:** Polidocanol Injection

## Key facts

- **NCT ID:** NCT03754140
- **Lead sponsor:** Melanoma Institute Australia
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-05-20
- **Primary completion:** 2022-12
- **Final completion:** 2022-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Unable to identify eligible patients within planned timeframe
- **Last updated:** 2022-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03754140

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03754140, "Intralesional Sclerosant for in Transit and Cutaneous Melanoma Metastases". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03754140. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*